Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Correction: In the previous press release, the number of TO2 in the table was incorrectly summed up, as all received subscription commitments were summed up instead of only those received from the board and management. In addition to commitments from the board and management, the Company has received subscription commitments amounting to 938,581 TO, or approximately SEK 1.7 million. The table is adjusted below.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.
Elicera Therapeutics AB (publ) ("Elicera" or the "Company") announces that members of the board of directors and executive management have entered into subscription commitments and provided non-binding commitments for exercising warrants of series TO2. This represents an investment of approximately SEK 0.7 million, which corresponds to 3.3 percent of the total number of outstanding warrants of series TO2. The subscription period for the warrants of series TO2 runs up to and including March 11, 2025.
As communicated via press release on February 25, 2025, the Company has received subscription commitments from board members and the executive management. The Company has now also received non-binding commitments for an additional total of 22,973 subscription warrants of series TO2, corresponding to approximately SEK 43 thousand and 0.2 percent of the total number of outstanding warrants of series TO2.
Elicera has now received subscription commitments and non-binding letters of intent from the following board members and executive officers:
| Warrant holder | Role in the Company | Number of TO2 | SEK |
| Jamal El-Mosleh | CEO | 151,900 | 281,015.00 |
| Di Yu | Head of Translational Research | 50,000 | 92,500.00 |
| Magnus Essand | CSO, Board member | 43,211 | 79,940.35 |
| Sharon Longhurst | Board member | 40,540 | 74,999.00 |
| Ingvar Karlsson | CFO | 33,600 | 62,160.00 |
| Agneta Edberg | Chairman of the Board | 27,027 | 49,999.95 |
| Margareth Jorvid | Board member | 21,700 | 40,145.00 |
| Christina Herder | Board member | 21,700 | 40,145.00 |
| Total | 389,678 | 720,904.30 |
The outcome of the exercise of the Warrants will be announced via a press release on or about March 13, 2025.
Complete terms and conditions for the warrants of series TO2 are available on the company's website www.elicera.com.
Summarized terms for the warrants of series TO2:
Exercise period: February 26, 2025 - March 11, 2025
Exercise price: SEK 1.85 per share
Issue size: 11,908,764 warrants of series TO2, which entitles to subscription of 11,908,764 shares. If all warrants are exercised, the Company will receive approximately SEK 22.0 million before issuing costs
Last day for trading with warrants of series TO2: Mars 7, 2025
Share capital and dilution: If all warrants are exercised the share capital will increase with SEK 500,168.088 from SEK 1,473,917.256 to SEK 1,974,085.344. If all warrants are exercised the number of shares and votes in the Company will increase with 11,908,764 shares, from 35,093,268 shares to 47,002,032 shares. In the event that all warrants of series TO2 are exercised, the dilution amounts to approximately 25.3 percent of the number of shares and votes in the Company
Please note that warrants that are not exercised no later than March 11, 2025, or sold no later than March 7, 2025, will expire without value. For warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.
How warrants are exercised:
Nominee-registered warrants (Custody account):
Subscription and payment by exercise of the Warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.
Direct-registered warrants (Securities account):
No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. The Warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.
The application form including instructions for payment is available at Elicera's website, www.elicera.com, and on Mangold Fondkommission AB's website, www.mangold.se.
Advisers
Mangold Fondkommission AB is financial adviser and Advokatfirman Delphi i Stockholm AB is legal advisor for Elicera regarding the warrants.